<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04744129</url>
  </required_header>
  <id_info>
    <org_study_id>H-20009266</org_study_id>
    <nct_id>NCT04744129</nct_id>
  </id_info>
  <brief_title>Headache Inducing Effect of NN414 in Migraine Patients</brief_title>
  <official_title>NN414's Effect in Cerebral Hemodynamics and Headache Induction in Migraine Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the role of KATP channels on the cerebral hemodynamic in migraine patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence and change of migraine attack</measure>
    <time_frame>Before (-10 min) and after infusion (+2 hours) of NN414 compared with before and after infusion of saline</time_frame>
    <description>Occurrence of migraine according to international criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cerebral hemodynamic</measure>
    <time_frame>Before (-10 min) and after infusion (+2 hours) of NN414 compared with before and after infusion of saline</time_frame>
    <description>Change on velocity of media cerebri artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and change of headache</measure>
    <time_frame>Before (-10 min) and after infusion (+2 hours) of NN414 compared with before and after infusion of saline</time_frame>
    <description>Occurrence of headache measured by numerical rating scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of diameter of the artery</measure>
    <time_frame>Before (-10 min) and after infusion (+2 hours) of NN414 compared with before and after infusion of saline</time_frame>
    <description>Change of diameter of superficial temporal artery and radial artery. The diameter will be measured by millimeter (mm).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Headache, Migraine</condition>
  <arm_group>
    <arm_group_label>NN414</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To investigate the role of NN414 compared with placebo in migraine patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To investigate the role of NN414 compared with placebo in migraine patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NN414</intervention_name>
    <description>To investigate the role of NN414 on cerebral hemodynamic in migraine patients</description>
    <arm_group_label>NN414</arm_group_label>
    <other_name>6-Chloro-3-[[1-methylcyclopropyl]amino]-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Migraine patients of both sexes.&#xD;
&#xD;
          -  18-60 years.&#xD;
&#xD;
          -  50-100 kg.&#xD;
&#xD;
          -  Women of childbearing potential must use adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Headache less than 48 hours before the tests start&#xD;
&#xD;
          -  Daily consumption of drugs of any kind other than oral contraceptives&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Cardiovascular disease of any kind, including cerebrovascular diseases.&#xD;
&#xD;
          -  Diabetes mellitus and other endocrinologic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Lili Kokoti, MD, PhD student</last_name>
    </contact>
    <investigator>
      <last_name>Messoud Ashina, Professor DHC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Lili Kokoti</investigator_full_name>
    <investigator_title>MD, PhD student, Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

